Autoimmunity against INS-IGF2 expressed in human pancreatic islets.
Type 1 diabetes (T1D)
3 is strongly associated with a selective autoimmune destruction of the pancreatic beta cells (1, 2) . The progressive loss of beta cells is often triggered at an early age (1, (3) (4) (5) and autoantibodies directed against islet autoantigens such as insulin, glutamic acid decarboxylase 65 (GAD65), islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8) are currently the best markers of the islet autoimmunity that precede the clinical onset of T1D (6, 7) . Insulin autoantibodies (IAA) may be the first islet autoantibodies to appear (8, 9) . However, it is the least frequent (10) as IAA are particularly common in patients at younger age of diagnosis (11). Persistent IAA in combination with any other islet autoantibody predicts T1D (12) . Insulin iodinated with 125 I is primarily used to detect IAA (13, 14) , however, IAA assays with iodinated insulin have proven difficult to standardize (15, 16) .
It has been speculated that the primary autoantigen is not matured insulin but rather proinsulin (17, 18) or perhaps preproinsulin (19, 20) . It was hypothesized that beta-cell endoplasmic reticulum (ER) fragments may become available to antigen presenting cells following e.g. viral lysis of beta cells (21) . prior to the development of IAA (22) . CD4+T cells seem preferentially to recognize (pro)insulin peptides from the B chain when presented on HLA DR4 or DQ8 molecules (for a review see (21) ).
IAA have been associated with HLA-DQ8 that is in strong linkage disequilibrium with DR4 (23) .
The B cell receptor (BCR) recognition may be broader as the binding site for IAA includes several B-chain amino acid residues (reviewed in (21) ). CD8+ T cells were reported to express TCR recognizing B-chain residues 10-18 (20) and 9-23 (24) or signal peptide residues 15-24 (25, 26) .
These observations suggest that the B-chain of insulin and perhaps also signal or B-C junction peptides may contribute to a pre(pro)insulin autoimmune response. It is expected that this response would be reflected by the appearance of pre(pro)insulin autoantibodies. The well established radiobinding assay (RBA) using coupled in vitro transcription translation of autoantigen cDNA effectively detects a number of conformation-dependent autoantibodies (27) (28) (29) (30) (31) (32) . The array data was summarized and normalized with Robust Multi-array Analysis (RMA) method using affy R package. All Data are MIAME compliant, and the raw data have been deposited in a MIAME database (GEO, accession number:
GSE 38642 and GSE 44035). Patients-Serum samples from 304 (54% male) patients with newly diagnosed T1D in the Better Diabetes Diagnosis (BDD) study (10, 35) .
Glucose-stimulated insulin release (GSIR)-
Patient sera were selected at random to represent one group of 152 patients with clinical onset at 1-5 years of age and another group of 152 patients at 15-18 years of age ( Table 1 ). The classification of diabetes was clinically confirmed six months after onset with T1D (10, 35) . HLA-DQ typing and analyses of islet autoantibodies against GAD65, insulin, IA-2 and ZnT8 (Table 1) were described in detail elsewhere (28, 35) .
Controls-Serum samples were obtained from a total of 355 healthy controls (Table 1) . Among these were 300 (47.3% males) 11.5-13.7 (range; median age 12.5) years old school children previously described (36) and analyzed for multiple autoantibodies (37, 38) . In addition, 55
healthy adult blood donors (54.5% males, n=30) aged 19.0-25.0 years (range; median age 23.0)
were also investigated (39) . Sepharose-bound radioactivity was converted into units per ml (U/ml) using individual standard curves generated by six step doubling dilutions
Preparation of INS-IGF2-INS-IGF2
(1:128 -1:4 dilutions) of high-titer T1D patient's sera with high reactivity for the INS-IGF2 antigen.
Three internal quality control samples, two from healthy subjects and one from a long term diabetes subjects were used in every assay.
Intra-assay coefficient of variation (CV) and inter-assay CV for duplicate determinations were 4.1% and 5.1%, respectively.
RBA for GAD65A and IA-2A-These autoantibodies were analyzed as described in detail elsewhere (35) . GAD65A and IA-2A levels were expressed as units per milliliter derived from the World Health Organization standard 97/550 (40) . Samples were considered positive if GAD65A levels were > 50 U/ml and IA-2A levels > 10 U/ml. The intra-assay CV for duplicates in the GAD65A assay was 7% and in the IA-2A 11%.
In the Diabetes Autoantibody Standardization
Program (DASP) 2010 workshop, the workshop sensitivity was 80% and specificity 99% for GAD65A and 60% sensitivity and 99% specificity for IA-2A.
RBA for ZnT8 R, W and Q -variant
autoantibodies-These autoantibodies were analyzed as previously described (28 PerkinElmer). Sepharose-bound radioactivity was converted into U/ml using individual standard curves generated by six step doubling dilutions
(1:512 -1:8 dilutions) of high-titer T1D patient's sera with high reactivity for IAA. Three internal quality control samples, two from healthy subjects and one from a long term diabetes subjects were used in every assay. Sepharose-bound radioactivity was converted into U/ml using individual standard curves generated by six step doubling dilutions of high-titer T1D patient's sera with high reactivity for each individual IAA.
Our assays showed comparable precision (intra-assay CV was 6.0% for IAA) and reproducibility (inter-assay CV) was 13.2%. Our laboratory participated in the DASP (14) 
RESULTS

Microarray gene expression in human pancreatic islets-
In vitro transcription translation of INS-IGF2
cDNA-INS-IGF2 cDNA, subjected to in vitro transcription translation in the presence of both The binding was displaced by about 50% at all serum dilutions by cold INS-IGF2 produced by in vitro transcription translation ( Figure 6, panel B) .
RBA for INS-IGF2 autoantibodies-
The data in Figure 6 , panel B also demonstrate that ND is not determined.
